V
ELDN icon

Veritable’s Eledon Pharmaceuticals ELDN Stock Holding History

Veritable’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,029
Closed -$17.9K – 250
2023
Q2 		$17.9K Hold
13,029
– – ﹤0.01% 888
2023
Q1 		$30.7K Buy
+13,029
New +$34.9K ﹤0.01% 885
2022
Q2 		– Sell
-33,092
Closed -$130K – 922
2022
Q1 		$130K Hold
33,092
– – ﹤0.01% 881
2021
Q4 		$146K Hold
33,092
– – ﹤0.01% 889
2021
Q3 		$205K Hold
33,092
– – ﹤0.01% 840
2021
Q2 		$262K Buy
+33,092
New +$312K ﹤0.01% 736

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return

Veritable's ELDN Position: Q3 2023 in Review

Veritable sold out of Eledon Pharmaceuticals (ELDN) in Q3 2023, closing a stake of 13,029 shares — an estimated $17.9K sold.

Veritable first reported a position in ELDN in Q2 2021 and held it in 6 quarters. The position peaked at $262K in Q2 2021. 28 funds tracked by Wall St. Rank hold ELDN as of Q3 2023.

  • Veritable reported no remaining Eledon Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Veritable sold 13,029 Eledon Pharmaceuticals shares in Q3 2023, an estimated $17.9K.
  • Veritable first reported a position in Eledon Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Veritable's Eledon Pharmaceuticals position peaked at $262K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.